Pro-calcitonin and inflammation in chronic hemodialysis;Pro-calcitonina e inflamación en hemodiálisis crónica

Medicina (Argentina)

Volumn 73, Issue 5, 2013, Pages 411-416

  Trimarchi, Hernán ^a   Dicugno, Mariana ^a   Muryan, Alexis ^a   Lombi, Fernando ^a   Iturbe, Leticia ^a   Raña, María S ^a   Young, Pablo ^a   Nau, Karin ^a   Iriarte, Romina ^a   Pomeranz, Vanesa ^a   Forrester, Mariano ^a   Karl, Alejandra ^a   Alonso, Mirta ^a  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

C reactive protein; Hemodialysis; Inflammation; Procalcitonin

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; MALNUTRITION INFLAMMATORY SCORE; OBSERVATIONAL STUDY; SEX DIFFERENCE; VASCULAR ACCESS;

C-REACTIVE PROTEIN; HEMODIALYSIS; INFLAMMATION; PROCALCITONIN;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; REFERENCE VALUES; RENAL DIALYSIS; SEX FACTORS; TIME FACTORS; VASCULITIS;

EID: 84886860855     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. European Renal Association European- Dialysis and Transplant Association (ERA-EDTA) report on management of renal failure in Europe. Causes of death. Nephrol Dial Transplant 1995; 10: S11-S12.
2. Lacson K, Owen W. Interactions between hemodialysis adequacy and nutrition in dialysis patients. Semin Dial 1999; 12: 112-119.
3. Stevenson. Inflammation and end-stage renal disease. Recent insights. Semin Dial 1998; 11: 119-123.
4. Assicot M, Gendrel D, Carsin H, Raymond J, Guibaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-518.
5. Maruna P, Nedelnikova K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res 2000; 49: S57-S61.
6. Wicher J, Bienvenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001; 38: 483-493.
7. Reinhart K, Meisner M. Biomarkers in the critically ill patient: Procalcitonin. Crit Care Clin 2011; 27: 253-263.
8. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions. Past, present and future. BMC Medicine 2011; 9: 107.
9. Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984, 167: 93-97.
10. Oberhoffer M, Stonans I, Russwurm S, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134: 49-55.
11. Mori KI, Noguchi M, Sumino Y, Sato F, Mimata H. Use of pro-calcitonin in patients on chronic hemodialysis: procalcitonin is not related with increased serum calcitonin. International Scholarly Research Network Urology 2012; 2012: 1-6.
12. Russwurm S, Stonans I, Stonane E. Procalcitonin and CGRP-I mRNA expression in various human tissues. Shock 2001; 16: 109-112.
13. Müller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86: 396-404.
14. Ulrich C, Keil K, Hermann W, Kuhlman M, Koehler H, Riegel W. Procalcitonin a further acute phase parameter in patients undergoing hemodialysis?. J Am Soc Nephrol 2000; 11: 501A.
15. Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 2002; 15: 297-301.
16. Chauveau P, Level C, Lasseur C, Bonarek H, Peuchant E, Montaudon D. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: A 2-year prospective study. J Renal Nutrition 2003; 13: 137-143.
17. Montagnana M, Lippi G, Tessitore N, et al. Procalcitonin values after dialysis is closely related to type of dialysis membrane. Scand J Clin Lab Invest 2009; 69: 703-707.
18. Karayaylali I, Seyrek N, Balal M, Paydas S, Cetiner S, Yaman A. Pre- and Post Hemodialysis procalcitonin levels and their relationships with immunoregulatory, pro-infammatory cytokines in chronic hemodialysis patients. Hemodial Int 2004; 8: 90.
19. Kalocheretis P, Revela I, Spanou E, Drouzas A, Makrini-otou I, Iatrou C. Strong correlation of B2-microglobulin (B2-m) with procalcitonin (PCT) in the serum of chronic hemodialysis patients: a role for infections in the dialysis-related amyloidosis? Ren Fail 2008; 30: 261-265.
20. Visvardis G, Griveas I, Fleva A, et al. Relevance of procal-citonin levels in comparison to other markers of infamma-tion in hemodialysis patients. Ren Fail 2005; 27: 429-434.
21. Lavín-Gómez B, Palomar-Fontanet R, Gago-Fraile M, et al. Infammation markers, chronic kidney disease, and renal replacement therapy. Adv Perit Dial 2011; 27: 33-37.
22. Dahaba AA, Rehak PH, List WF. Procalcitonin and C-re-active protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003; 29: 579-583.
23. Herget-Rosenthal S, Marggraf G, Pietruck F, et al. Procalci-tonin for accurate detection of infection in haemodialysis. Nephrol Dial Transpl 2001; 16: 975-979.
24. Herget-Rosenthal S, Klein T, Marggraf G, et al. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol 2005; 61: 180-186.
25. Level C, Chauveau P, Delmas Y, et al. Procalcitonin: a new marker of infammation in haemodialysis patients?. Nephrol Dial Transplant 2001; 16: 980-986.
26. Opatrná S, Klaboch J, Opatrný K Jr, et al. Procalcitonin levels in peritoneal dialysis patients. Perit Dial Int 2005; 25: 470-472.
27. Guz G, Colak B, Hizel K, et al. Procalcitonin and conventional markers of infammation in peritoneal dialysis patients and peritonitis. Perit Dial Int 2006; 26: 240-248.
28. Lam MF, Leung JCK, Lam CW, et al. Procalcitonin fails to differentiate infammatory status or predict longterm outcomes in peritoneal dialysis-associated peritonitis. Perit Dial Int 2008; 28: 377-384.
29. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chem-other 2011; 66: S33-S40.
30. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic infammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010; 159: 253-264.
31. Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhardt K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 2001; 18: 79-87.
32. Herbelin A, Nguyen AT, Zingraff J, Urena P, Deschamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990; 37: 116-125.
33. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Din-arello CA. Plasma levels of IL-1β, TNF-β, and their specifc inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896.
34. Pahl MV, Vaziri ND, Yuan J, Adler SG. Upregulation of monocyte/macrophage hgfn (gpnmb/ osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol 2010; 5: 56-61.
35. Hoffmann G, Czechowski M, Schoesser M, Schobersberger W. Procalcitonin amplifIes inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med 2002; 30: 2091-2095.
36. Wagner KE, Martinez JM, Vath SD. Early immunoneu-tralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med 2002; 30: 2313-2321.
37. Nylen ES, Whang KT, Snider RH. Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by proc-alcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26: 1001-1006.
38. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
39. Ridker PM, Hennekens CH, Buring JE. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 101: 1767-1772.
40. Stenvinkel P. InfLammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002; 17: S33-S38.